Table 2.

Univariate analysis of correlation between hematologic toxicities (i.e., change in cell number over time) and overall survival (OS) after sunitinib treatment. Data are shown as hazard ratios with 95% CI

	OS
Cell type	Day 14	Day 28	Day 42
WBCs	5.45 [1.13,26.32]	3.28 [0.51,21.00]	1.69 [0.36,7.90]
	n=32	n=27	n=23
P value1	0.035	0.21	0.51
Padj value2	0.097	0.32	0.55
Lymphocytes	1.24 [0.53,2.90]	1.21 [0.30,4.89]	0.05 [0.01,0.46]
	n=32	n=27	n=23
P value	0.62	0.79	0.0079
Padj value	0.79	0.79	0.026
Hemoglobin	0.01 [0.0,3.26]	0.36 [0.01,21.64]	0.03 [0.00,2.18]
	n=32	n=27	n=23
P value	0.11	0.63	0.11
Padj value	0.18	0.63	0.18
Monocytes	2.29 [0.81,6.45]	5.72 [1.79,18.27]	0.59 [0.11,3.11]
	n=31	n=27	n=23
P value	0.12	0.0033	0.53
Padj value	0.16	0.0098	0.57
Platelets	1.35 [0.58,3.13]	8.00 [1.61,39.79]	1.84 [0.37,9.19]
	n=32	n=27	n=23
P value	0.49	0.011	0.46
Padj value	0.5	0.033	0.5
Neutrophils	7.50 [2.00,28.07]	6.45 [0.81,51.06]	2.24 [0.86,5.83]
	n=32	n=27	n=23
P value	0.0028	0.077	0.097
Padj value	0.0076	0.11	0.11

Data are shown as hazard ratios (HR) associated with doubling of baseline hematologic counts with respect to the population, after adjusting for BCLC stage. All lab measurements were log-transformed. Note that HR > 1 indicates diminished hazard of death associated with decreased values.

¹P-values are from Wald test;

²Padj-values are P values adjusted for multiple comparisons.